The archive
391 stories, newest first — page 4 of 17.
Women's Health
The FDA approved first-line sacituzumab govitecan plus pembrolizumab for unresectable or metastatic TNBC with PD-L1 CPS ≥10, making validated biomarker testing pivotal to treatment selection.
Rayan Salih · 7 min read
Oncology
Traditional approval makes selpercatinib an established tumor-agnostic option for qualifying RET fusion-positive advanced solid tumors in adults and children age 2 years and older.
Rayan Salih · 7 min read
Oncology
Median overall survival was reported at 13.2 months with daraxonrasib versus 6.6 months with chemotherapy in KRAS-mutant metastatic pancreatic cancer, but comparative uncertainty limits practice implications.
Rayan Salih · 7 min read
Infectious Disease
A South African randomized trial supports six-month treatment for eligible people with rifampicin-resistant tuberculosis, although safety, mortality, and US applicability require careful review.
Rayan Salih · 7 min read
Cardiology
The 2026 multisociety guideline defines a unified pathway for evaluating cardiovascular, kidney and metabolic risk, particularly when disease or risk factors overlap.
Rayan Salih · 7 min read
Cardiology
The DAPT-MVD citation alone does not provide enough verified numerical detail to weigh another year of clopidogrel plus aspirin after multivessel PCI.
Rayan Salih · 6 min read
Endocrinology & Metabolism
A secondary analysis found that finerenone reduced cardiovascular and kidney events across CKM stages in adults with type 2 diabetes and CKD, while favoring CKM stage regression over progression.
Dr. Abu Bakar · 7 min read
Endocrinology & Metabolism
Updated evidence supports SGLT inhibition across heart failure phenotypes, with the clearest benefit in preventing worsening heart failure. Mortality and safety findings require more nuanced interpretation.
Dr. Abu Bakar · 7 min read
Health Policy
A new WHO compendium standardizes clinical, operational and monitoring terminology for hypertension-control programs, giving health systems a shared basis for implementation, reporting and performance comparisons.
Dr. Abu Bakar · 6 min read
Infectious Disease
WHO has revised weight-band dosing and preferred antiretroviral regimens for newborns, infants and children. The changes affect neonatal prophylaxis, treatment initiation and dose review as children grow.
Dr. Abu Bakar · 6 min read
Oncology
The FDA has moved lutetium Lu-177 vipivotide tetraxetan into PSMA-positive metastatic hormone-sensitive prostate cancer when combined with an androgen receptor pathway inhibitor.
Dr. Abu Bakar · 7 min read
Health Policy
The FDA has ended emergency-use authorizations for COVID-19 diagnostics and devices. US laboratories, health systems and manufacturers must reassess legal status, inventory, validation and procurement.
Rayan Salih · 6 min read
Oncology
The FDA expanded enfortumab vedotin plus pembrolizumab around cystectomy to adults with muscle-invasive bladder cancer regardless of cisplatin eligibility.
Rayan Salih · 7 min read
Health Policy
The 2026 joint guideline links lipid management to CKM stage and PREVENT-ASCVD risk, with explicit LDL-C, non-HDL-C and apoB goals for US adults.
Rayan Salih · 7 min read
Cardiology
The 2026 guideline retains a 130/80 mm Hg diagnostic threshold but links medication timing to cardiovascular, diabetes and kidney risk. Most treated adults share a target below 130/80 mm Hg.
Rayan Salih · 7 min read
Oncology
Perioperative enfortumab vedotin plus pembrolizumab improved survival and pathologic complete response versus cisplatin–gemcitabine in cisplatin-eligible adults undergoing cystectomy.
Rayan Salih · 7 min read
Infectious Disease
CDC reports 1,645 confirmed domestically acquired cases since May 1, 2026. Prolonged or relapsing watery diarrhea should prompt consideration of Cyclospora-specific stool testing.
Rayan Salih · 7 min read
Oncology
A phase 3 trial found that daily ensartinib substantially prolonged disease-free survival after chemotherapy and complete resection of stage IB-IIIB ALK-positive NSCLC.
Dr. Abu Bakar · 6 min read
Clinical Briefs
Fresenius Kabi recalled one lot of morphine sulfate injection after a label mix-up could expose patients to hydromorphone, creating a risk of opioid overdose and respiratory depression.
Rayan Salih · 6 min read
Cardiology
The 2026 consensus sharpens how heart failure should be identified and documented when symptoms, cardiac abnormalities, biomarkers and evidence of congestion disagree.
Rayan Salih · 7 min read
Endocrinology & Metabolism
The FDA expanded teplizumab to patients ages 8–17 with stage 3 type 1 diabetes diagnosed within six weeks, based on evidence that it slows loss of insulin-producing function.
Rayan Salih · 7 min read
Cardiology
FDA approval makes enlicitide the first oral PCSK9 inhibitor for adults who need additional LDL-C lowering despite maximally tolerated statins, including those with heterozygous familial hypercholesterolemia.
Rayan Salih · 6 min read
Neurology
Selected patients with salvageable brain tissue may benefit from IV thrombolysis 4.5 to 24 hours after ischemic stroke onset, although symptomatic intracranial hemorrhage risk is higher.
Dr. Abu Bakar · 6 min read
Cardiology
OPTIMA-AF supports stopping the P2Y12 inhibitor after 1 month in selected patients with atrial fibrillation undergoing PCI, reducing important bleeding without an apparent loss of thromboembolic protection.
Egbavwe Pela · 6 min read